Category: biotech

.Simply a few quick weeks after gaining an FDA Fast lane tag for its investigational BTK degrader in certain blood stream cancers, BeiGene has been

.AbbVie has gone back to the resource of its own antipsychotic goliath Vraylar in search of another smash hit, paying for $25 million beforehand to

.On the same day that some Parkinson’s disease medicines are actually being called into question, AbbVie has actually declared that its late-stage monotherapy prospect has

.Monopar Therapies is actually recuperating a medicine coming from the dump of AstraZeneca’s rare illness pipeline. It has actually accredited ALXN-1840, a prospect for the

.AstraZeneca has actually used artificial intelligence to develop a special biomarker for its Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), expecting to vary the antibody-drug conjugate (ADC)